Jim Cramer on Immunome: "If You Want to Speculate on It, Fine"

Immunome, Inc. (NASDAQ:IMNM) is one of the stocks Jim Cramer offered insights on. When a caller inquired about the stock, Cramer stated:

“This company’s losing so much money, I know, but it’s Dr. Siegall… So therefore, if you want to speculate on it, fine. But we do not think that you’re investing.”

Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotech company that focuses on developing targeted cancer treatments, with a leading drug candidate in late-stage testing and another in early clinical trials. The company’s pipeline also includes earlier-stage therapies aimed at treating solid tumors with more precise approaches. On December 15, 2025, it announced that the Phase 3 RINGSIDE trial of varegacestat showed strong results in patients with progressing desmoid tumors.

The drug showed a reduction of risk of disease progression or death by 84% versus placebo. Additionally, it delivered a 56% response rate compared with 9% for placebo, and reduced tumor volume by 83%, and mostly only showed mild to moderate side effects. Immunome, Inc. (NASDAQ:IMNM) plans to submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026. Sarcoma medical oncologist and drug development specialist and RINGSIDE primary investigator, Mrinal M. Gounder, M.D. said:

“The progression-free survival benefit, high response rate and reduction in tumor volume with varegacestat in the RINGSIDE trial are striking. These findings elevate the role of GSIs and confirm varegacestat could become standard of care in the treatment of desmoid tumors.”

While we acknowledge the potential of IMNM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.